Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

J. Eron, Joseph; Clotet, Bonaventura; Durant, J.; Katlama, Christine; Kumar, Princy; Lazzarin, Adriano; Poizot‐Martin, Isabelle; Richmond, Gary; Soriano, Vincent; Ait‐Khaled, Mounir; Fujiwara, Tamio; Huang, Jenny; Min, Sherene; Vavro, Cindy; Yeo, Jane; the VIKING Study Group, for; Walmsley, Sharon; Cox, Joseph; Reynes, Jacques; Morlat, Philippe; Vittecoq, Daniel; Livrozet, Jean‐Michel; Viciana Fernández, Pompeyo; M. Gatell, José; DeJesus, Edwin; DeVente, Jerome; Lalezari, Jacob; McCurdy, Lewis; A. Sloan, Louis; Young, Benjamin; LaMarca, Anthony; Hawkins, Trevor

doi:10.1093/infdis/jis750

Public

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

Published in The Journal of Infectious Diseases • Dec 7, 2012

Authors:

Joseph J. Eron

Bonaventura Clotet

J. Durant

Abstract

BACKGROUND: Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in vitro. This phase IIb study assessed the activity of DTG in HIV-1-infected subjects with genotypic evidence of RAL re...

Subject

Dolutegravir

Raltegravir

Regimen

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!